For research use only
| Cat No. | ABC-TC0709 |
| Product Type | Rat Breast Cancer Cell Lines |
| Species | Wistar/Furth Rat |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Adenocarcinoma of the rat mammary gland |
| Product Code | MT450TC, MT 450TC, mt-450tc |
Tissue culture cell line of MT-W45 derived from MT-W9A. Metastasize massively to lymph nodes, lung, liver, kidney, etc
MT‑450TC is a female rat (Rattus norvegicus, Wistar/Furth) mammary adenocarcinoma cell line, established from a tumor that arose in situ from the MT-W45 cell line. The MT-W45 cell line was itself derived from the MT-W9A cell line. These cells exhibit epithelial-to-mesenchymal morphology changes and display adherent growth or growth as tight clusters. Cytogenetic data indicate pseudohexadecaploid chromosome numbers, reflecting high genomic instability associated with tumor progression. MT‑450TC is highly tumorigenic and metastatic, forming aggressive tumors in syngeneic Wistar/Furth rats with frequent metastases to lymph nodes, lung, liver, and kidney. Expression profiling reveals low or marginal estrogen receptor protein (ERP). This metastasis-prone phenotype makes MT‑450TC a strong model for studying tumor dissemination and therapy. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from mycoplasma, fungi, yeast, and bacteria.
| Product Code | MT450TC, MT 450TC, mt-450tc |
| Species | Wistar/Furth Rat |
| Cat.No | ABC-TC0709 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Adenocarcinoma of the rat mammary gland |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Breast Cancer Cell Lines |
MT‑450TC is widely used in rat syngeneic tumor models to investigate mammary carcinoma metastasis, including lymphatic and distant organ spread. Its aggressive metastatic nature allows in vivo evaluation of anti-metastatic drugs, invasion assays, and therapeutic interventions. In vitro, it’s suitable for testing chemotherapeutic efficacy, angiogenesis inhibition, and tumor cell migration. MT‑450TC also supports molecular studies on metastatic mechanisms and genomic instability in breast cancer. Its reproducible tumor formation in immunocompetent hosts makes it valuable for immuno-oncology research and preclinical evaluation of novel cancer therapies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
